This article was originally published in The Gray Sheet
Nets $141.2 mil. from a secondary offering of approximately 2.6 mil. shares of common stock at $68.375 each, including overallotment shares. The infusion system maker had planned an offering of 2.3 mil. shares, including 300,000 shares offered by a selling shareholder (1"The Gray Sheet" July 5, p. 26). Overallotment shares included 172,500 purchased from the company and 172,500 shares from a selling stockholder. The deal was underwritten by Warburg Dillon Read LLC. Co-managers of the offering included Hambrecht & Quist LLC, ING Baring Furman Selz LLC and Volpe Brown Whelan & Company
You may also be interested in...
FDA approval of MiniMed's continuous glucose monitoring system (CGMS) June 16 helped sweeten the company's stock price during the month.
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.